GlassScriptPhysician profile
Krista Pembroke
NPI 1043920606
$4,558.79
in general payments reported to CMS, 2019-2025
20 companies · $1,159 in 2025
The $1,159 reported for 2025 was more than what 83% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $2,375 · 2024: $1,024 · 2025: $1,159.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,559.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,558.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $679.96 | 2023-2025 | |
| Axsome Therapeutics, INC. | $607.08 | 2023-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $574.69 | 2023-2025 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $491.77 | 2023-2025 | Caplyta |
| Alkermes, INC. | $407.92 | 2023-2025 | Aristada, Lybalvi |
| Vanda Pharmaceuticals INC. | $238.32 | 2024-2025 | Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $202.10 | 2023-2025 | Trintellix |
| Tris Pharma INC | $196.40 | 2023-2025 | Dyanavel Xr |
| E.R. Squibb & Sons, L.L.C. | $186.45 | 2024-2025 | Cobenfy |
| Ironshore Pharmaceuticals INC. | $183.14 | 2023-2024 | Jornay Pm |
| Otsuka America Pharmaceutical, INC. | $180.85 | 2023-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Lundbeck LLC | $150.97 | 2023-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $130.97 | 2023-2024 | Ingrezza |
| Corium, LLC | $74.54 | 2023 | Azstarys |
| Collegium Pharmaceutical, INC. | $64.40 | 2025 | Jornay Pm |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $57.89 | 2023-2025 | Adzenys Xr-Odt |
| Almatica Pharma LLC | $53.47 | 2023-2025 | Loreev Xr, Gralise |
| Supernus Pharmaceuticals, INC. | $45.37 | 2024-2025 | Qelbree |
| Idorsia Pharmaceuticals US INC | $16.88 | 2024 | Quviviq |
| Brainsway USA INC | $15.62 | 2025 | Deep Tms System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Krista Pembroke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.